Rucaparib Camsylate Patent Expiration

Rucaparib Camsylate is Used for treating cancers associated with deleterious BRCA mutations, such as epithelial ovarian, fallopian tube, primary peritoneal cancer, and metastatic castration-resistant prostate cancer. It was first introduced by Pharmaand Gmbh in its drug Rubraca on Dec 19, 2016.


Rucaparib Camsylate Patents

Given below is the list of patents protecting Rucaparib Camsylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Rubraca US10130636 High dosage strength tablets of rucaparib Aug 17, 2035 Pharmaand
Rubraca US9987285 High dosage strength tablets of rucaparib Aug 17, 2035 Pharmaand
Rubraca US8859562 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Aug 04, 2031 Pharmaand
Rubraca US10278974 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb 10, 2031 Pharmaand
Rubraca US8754072 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one Feb 10, 2031 Pharmaand
Rubraca US9045487 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb 10, 2031 Pharmaand
Rubraca US9861638 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb 10, 2031 Pharmaand
Rubraca US8071579 DNA damage repair inhibitors for the treatment of cancer Aug 12, 2027 Pharmaand
Rubraca US8143241 DNA damage repair inhibitors for treatment of cancer Aug 12, 2027 Pharmaand
Rubraca US7351701 Therapeutic compounds Jul 23, 2024

(Expired)

Pharmaand
Rubraca US7531530 Therapeutic compounds Jul 23, 2024

(Expired)

Pharmaand
Rubraca US6495541 Tricyclic inhibitors of poly(ADP-ribose) polymerases Nov 22, 2023

(Expired)

Pharmaand



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rucaparib Camsylate's patents.

Given below is the list recent legal activities going on the following patents of Rucaparib Camsylate.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 16 Nov, 2022 US9045487
Payment of Maintenance Fee, 4th Year, Large Entity 26 Oct, 2022 US10278974
Payment of Maintenance Fee, 4th Year, Large Entity 04 May, 2022 US10130636
Payment of Maintenance Fee, 8th Year, Large Entity 01 Dec, 2021 US8754072
Payment of Maintenance Fee, 4th Year, Large Entity 17 Nov, 2021 US9987285
Payment of Maintenance Fee, 4th Year, Large Entity 23 Jun, 2021 US9861638
Change in Power of Attorney (May Include Associate POA) 05 Mar, 2021 US10130636
Correspondence Address Change 04 Mar, 2021 US9987285
Correspondence Address Change 04 Mar, 2021 US10130636
Change in Power of Attorney (May Include Associate POA) 04 Mar, 2021 US9987285


Rucaparib Camsylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List